Date:11/16/2009

(472) (5,831) ---------- ---------- Total costs and expenses 480,619 523,568 ---------- ---------- Operating loss (380,619) (423,568) Other income: Interest income 65,440 569,710 Gain (loss) on redemption of securities 157,528 (33,562) Investment reduction to net asset value -- (377,067) ---------- ---------- Loss before provision for income taxes (157,651) (264,487) Provision for income taxes -- 1,658 ---------- ---------- Net (loss) ($157,651) ($266,145) ========== ========== Basic and diluted (loss) per weighted average share of common stock outstanding ($0.01) ($0.02) ========== ========== Weighted average shares of common stock outstanding - basic and diluted 13,144,040 13,144,040 ========== ==========

SOURCE Cadus Corporation

'/>"/>

SOURCE Cadus Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Cadus Reports Third Quarter 2007 Results
2. Cadus Reports Second Quarter 2007 Results
3. Cadus Reports First Quarter 2008 Results
4. Cadus Reports Second Quarter 2008 Results
5. Cadus Reports Second Quarter 2009 Results
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results